1. Kuter D.J., Newland A., Chong B.H., Rodeghiero F., Romero M.T., Pabinger I., Chen Y., Wang K., Mehta B., Eisen M. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies // Br. J. Haematol. - 2019. - Vol. 185, No. 3. - P. 503-513. https://doi.org/10.1111/bjh.15803
2. Birocchi S., Podda G.M., Manzoni M., Casazza G., Cattaneo M. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review // Platelets. - 2021. - Vol. 32, No. 2. - P. 216-226. https://doi.org/10.1080/09537104.2020.1745168
3. Pietras N.M., Pearson-Shaver A.L. Immune Thrombocytopenic Purpura. 2022 May 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. - 2022.
4. Newland A., Godeau B., Priego V., Viallard J.F., López Fernández M.F., Orejudos A., Eisen M. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study // Br. J. Haematol. - 2016. - Vol. 172, No. 2. - P. 262-273. https://doi.org/10.1111/bjh.13827
5. Pasquet M., Aladjidi N., Guiton C., Courcoux M.F., Munzer M., Auvrignon A., Lutz P., Ducassou S., Leroy G., Munzer C., Leverger G.; Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE). Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience // Br. J. Haematol. - 2014. - Vol. 164, No. 2. - P. 266-271. https://doi.org/10.1111/bjh.12609
6. Vishnu P., Aboulafia D.M. Long-term safety and efficacyof romiplostim for treatment of immune thrombocytopenia // J. Blood Med. - 2016. - Vol. 7. - P. 99-106. https://doi.org/10.2147/JBM.S80646.
7. Wolff-Holz E., Tiitso K., Vleminckx C., Weise M. Evolution of the EU Biosimilar Framework: Past and Future // BioDrugs. - 2019. - Vol. 33, No. 6. - P. 621-634. https://doi.org/10.1007/s40259-019-00377-y
8. Сунцова Е.В., Чиквина И.И., Садовская М.Н., Коцкая Н.Н., Хачатрян Л.А., Байдильдина Д.Д., Калинина И.И., Петрова У.Н., Пшонкин А.В., Лутфуллин И.Я., Лемазина Е.Н., Осипова И.В., Галеева А.В., Наумова О.С., Фисюн И.В., Быкова Г.В., Казарян Г.Р., Масчан А.А., Новичкова Г.А. Применение ромиплостима при впервые выявленной иммунной тромбоцитопении у детей // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. - 2020. - Т. 19, № 1. - С. 18-26. https://doi.org/10.24287/1726-1708-2020-19-1-18-26
9. Bussel J.B., Soff G., Balduzzi A., Cooper N., Lawrence T., Semple J.W. A Review of Romiplostim Mechanism of Action and Clinical Applicability // Drug Des. Devel. Ther. - 2021. - Vol. 15. - P. 2243‒2268. https://doi.org/10.2147/DDDT.S299591
10. Yang A.S. Development of romiplostim: a novel engineered peptibody // Semin. Hematol. - 2015. - Vol. 52, No. 1. - P. 12-15. https://doi.org/10.1053/j.seminhematol.2014.10.007
11. Kuter D.J. Romiplostim // Cancer Treat. Res. - 2011. - Vol. 157. P. 267-288. https://doi.org/10.1007/978-1-4419-7073-2_16.
12. Bussel J.B., Kuter D.J., George J.N., McMillan R., Aledort L.M., Conklin G.T., Lichtin A.E., Lyons R.M., Nieva J., Wasser J.S., Wiznitzer I., Kelly R., Chen C.F., Nichol J.L. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP // N. Engl. J. Med. - 2006. - Vol. 355, No. 16. - P. 1672-1681. https://doi.org/10.1056/NEJMoa054626. Erratum in: N Engl J Med. - 2006. - Vol. 355, No. 19. - Art. No. 2054.
13. Kuter D.J., Bussel J.B., Lyons R.M., Pullarkat V., Gernsheimer T.B., Senecal F.M., Aledort L.M., George J.N., Kessler C.M., Sanz M.A., Liebman H.A., Slovick F.T., de Wolf J.T., Bourgeois E., Guthrie T.H. Jr., Newland A., Wasser J.S., Hamburg S.I., Grande C., Lefrère F., Lichtin A.E., Tarantino M.D., Terebelo H.R., Viallard J.F., Cuevas F.J., Go R.S., Henry D.H., Redner R.L., Rice L., Schipperus M.R., Guo D.M., Nichol J.L. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial // Lancet. - 2008. - Vol. 371, No. 9610. - P. 395-403. https://doi.org/10.1016/S0140-6736(08)60203-2
14. Kuter D.J., Rummel M., Boccia R., Macik B.G., Pabinger I., Selleslag D., Rodeghiero F., Chong B.H., Wang X., Berger D.P. Romiplostim or standard of care in patients with immune thrombocytopenia // N. Engl. J. Med. - 2010. - Vol. 363, No. 20. - P. 1889-1899. https://doi.org/10.1056/NEJMoa1002625
15. Shirasugi Y., Ando K., Miyazaki K., Tomiyama Y., Okamoto S., Kurokawa M., Kirito K., Yonemura Y., Mori S., Usuki K., Iwato K., Hashino S., Wei H., Lizambri R. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial // Int. J. Hematol. - 2011. - Vol. 94, No. 1. - P. 71-80. https://doi.org/10.1007/s12185-011-0886-8.
16. Beck A., Reichert J.M. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies // MAbs. 2011. - Vol. 3, No. 5. - P. 415-416. https://doi.org/10.4161/mabs.3.5.17334
17. Czajkowsky D.M., Hu J., Shao Z., Pleass R.J. Fc-fusion proteins: new developments and future perspectives // EMBO Mol. Med. - 2012. - Vol. 4, No. 10. - P. 1015-1028. https://doi.org/10.1002/emmm.201201379
18. Lee C.H., Delidakis G. Engineering IgG1 Fc Domains That Activate the Complement System // Methods Mol. Biol. - 2022. - Vol. 2421. - P. 187-200. https://doi.org/10.1007/978-1-0716-1944-5_13
19. Sommarhem A. Resistance mechanisms of non-Hodgkin lymphomas against Rituximab treatment. Helsinki: University of Helsinki, 2007.
20. Amoroso A., Hafsi S., Militello L., Russo A.E., Soua Z., Mazzarino M.C., Stivala F., Libra M. Understanding rituximab function and resistance: implications for tailored therapy // Front. Biosci. (Landmark Ed). - 2011. - Vol. 16, No. 2. - P. 770-782. https://doi.org/10.2741/3719
21. Cerny T., Borisch B., Introna M., Johnson P., Rose A.L. Mechanism of action of rituximab // Anticancer Drugs. - 2002. - Vol. 13 (Suppl 2). - P. 3-10. https://doi.org/10.1097/00001813-200211002-00002
22. Pescovitz M.D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action // Am. J. Transplant. - 2006. - Vol. 6(5 Pt 1). - P. 859-866. https://doi.org/10.1111/j.1600-6143.2006.01288.x
23. Winkler M.T., Bushey R.T., Gottlin E.B., Campa M.J., Guadalupe E.S., Volkheimer A.D., Weinberg J.B., Patz E.F. Jr. Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. // PLoS One. - 2017. - Vol. 12, No. 6. - e0179841. https://doi.org/10.1371/journal.pone.0179841
24. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., Lindorfer M.A., van de Winkel J.G., Parren P.W., Taylor R.P. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX // J. Immunol. - 2009. - Vol. 183, No. 1. - P. 749-758. https://doi.org/10.4049/jimmunol.0900632